Chemokine System-Therapeutic Target for Many Diseases (original) (raw)

Interfering with chemokines and chemokine receptors as potential new therapeutic strategies

Mario D'Elios

Expert Opinion on Therapeutic Patents, 2008

View PDFchevron_right

Targeting chemokines: new drugs for old diseases

Michael Portelli

Synapse

View PDFchevron_right

Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human

Mark Holbrook

Biochemical Pharmacology, 2005

View PDFchevron_right

Chemokines: progress toward identifying molecular targets for therapeutic agents

Adit N

Trends in Biotechnology, 1996

View PDFchevron_right

Chemokine inhibition ‒ why, when, where, which and how?

Montserrat Camps

Biochemical Society Transactions, 2004

View PDFchevron_right

The Molecular Basis of the Chemokine/Chemokine Receptor Interaction—Scope for Design of Chemokine Antagonists

Sami B Alouani

Methods, 1996

View PDFchevron_right

Chemokine receptors (version 2020.5) in the IUPHAR/BPS Guide to Pharmacology Database

Mette Rosenkilde

IUPHAR/BPS Guide to Pharmacology CITE, 2020

View PDFchevron_right

The chemokine receptor CCR5 in the central nervous system

Renier Myburgh

Progress in Neurobiology, 2011

View PDFchevron_right

Chemokines and chemokine receptors: their manifold roles in homeostasis and disease

Jiming Wang

Cellular & molecular immunology, 2004

View PDFchevron_right

Clinical relevance of chemokines

Brian Duchateau

Clinical Immunology Newsletter, 1997

View PDFchevron_right

Chemokine Receptor 3 by Affecting Its Interaction with CC Anti-HIV Activity of Human Eotaxin Chemotactic Potency, But Not the Down-Regulates the Eosinophil CD26/Dipeptidyl-Peptidase IV

Dominique Schols, P. Proost

View PDFchevron_right

Identification and Characterization of INCB9471, an Allosteric Noncompetitive Small-Molecule Antagonist of C-C Chemokine Receptor 5 with Potent Inhibitory Activity against Monocyte Migration and HIV-1 Infection

Swamy Yeleswaram, Peggy Scherle, Robert Newton

Journal of Pharmacology and Experimental Therapeutics, 2011

View PDFchevron_right

Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1

C. Mallari

The Journal of biological chemistry, 2000

View PDFchevron_right

Structure of the Chemokine receptor CCR5 -HIV entry inhibit complex

Qiuxiang TAN

View PDFchevron_right

Function, diversity and therapeutic potential of the N-terminal domain of human chemokine receptors

Martyna Szpakowska, Nico van Nuland

Biochemical Pharmacology, 2012

View PDFchevron_right

Chemokines in health and disease

Dayanidhi Raman, Ann Richmond

Experimental Cell Research, 2011

View PDFchevron_right

Activation of CCR5 by Chemokines Involves an Aromatic Cluster between Transmembrane Helices 2 and 3

Shoshana Wodak

Journal of Biological Chemistry, 2002

View PDFchevron_right

Allosteric Model of Maraviroc Binding to CC Chemokine Receptor 5 (CCR5)

Esther Kellenberger

Journal of Biological Chemistry, 2011

View PDFchevron_right

Current status of chemokine receptor inhibitors in development

Maria Candida Cesta

Immunology Letters, 2012

View PDFchevron_right

Membrane-Bound CC Chemokine Inhibitor 35K Provides Localized Inhibition of CC Chemokine Activity In Vitro and In Vivo

David Greaves

The Journal of Immunology, 2006

View PDFchevron_right

Structure of the CCR5 Chemokine Receptor-HIV Entry Inhibitor Maraviroc Complex

Ting Li

Science, 2013

View PDFchevron_right

Chemokine receptor (CCR5) expression in human kidneys and in the HIV infected macaque1

David Anderson, Kelly Hudkins

Kidney International, 1998

View PDFchevron_right

Chemokines and Their Receptors in Central Nervous System Disease

Knut Biber

Current Drug Targets, 2006

View PDFchevron_right

Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV- …

Mayaki Samson

Journal of …, 1997

View PDFchevron_right

Chemokines and disease

craig gerard

Nature Immunology, 2001

View PDFchevron_right

Chemokine receptors in GtoPdb v.2023.1

Mette Rosenkilde

IUPHAR/BPS Guide to Pharmacology CITE

View PDFchevron_right

The Ligands of CXC Chemokine Receptor 3, I-TAC, Mig, and IP10, Are Natural Antagonists for CCR3

Giuseppe Bardi

Journal of Biological Chemistry, 2001

View PDFchevron_right

β-Chemokine MDC and HIV-1 Infection

Monica Tsang

Science, 1998

View PDFchevron_right

Mechanisms of Regulation of the Chemokine-Receptor Network

Zil E Huma

International journal of molecular sciences, 2017

View PDFchevron_right

Molecular mechanism of desensitization of the chemokine receptor CCR-5: receptor signaling and internalization are dissociable from its role as an HIV-1 co-receptor

Stephen Ferguson

The EMBO Journal, 1997

View PDFchevron_right

Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity

David Price

Antimicrobial Agents and Chemotherapy, 2005

View PDFchevron_right

Chemokines and Chemokine Receptors

Manel Juan

eLS, 2001

View PDFchevron_right

International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the Extended Family of Chemokine Receptors and Introducing a New Nomenclature for Atypical Chemokine Receptors

Mette Rosenkilde

Pharmacological Reviews, 2013

View PDFchevron_right